MedTrace Logo

Vitamin D and Inflammatory Markers of Cardiovascular Disease in African Americans With Type 2 Diabetes

NCT01153243 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2011-04-07

No results posted yet for this study

Summary

Recent clinical trials in non diabetics showed that vitamin D supplementation markedly reduced serum levels of C-reactive protein (CRP), interleukin-6, and tissue matrix metallo-proteinases. Our study objective is to evaluate if administration of vitamin D in African Americans with hypovitaminosis D and DM Type 2 decreases serum levels of inflammatory/thrombotic markers such as CRP: Highly Sensitive C Reactive Protein.

Conditions

Interventions

DRUG

Ergocalciferol

Active Comparator: Ergocalciferol The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)

DRUG

Placebo pill

The investigators will give control group 12 weeks of 1 placebo pill every week.

Sponsors & Collaborators

  • Rush University

    collaborator OTHER

  • Cook County Health

    lead OTHER_GOV

Principal Investigators

  • Leon Fogelfeld, MD · Cook County Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2010-06-30
Completion
2011-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01153243 on ClinicalTrials.gov